Spyre Therapeutics Dirección
Dirección controles de criterios 0/4
El CEO de Spyre Therapeutics' es Cameron Turtle , nombrado en Oct 2023, tiene una permanencia de menos de un año. compensación anual total es $16.17M, compuesta por 1.7% salario y 98.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.47% de las acciones de la empresa, por valor de $20.80M. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 1.2 años, respectivamente.
Información clave
Cameron Turtle
Chief Executive Officer (CEO)
US$16.2m
Compensación total
| Porcentaje del salario del CEO | 1.7% |
| Permanencia del CEO | less than a year |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 1.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
Feb 10
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$186m |
| Mar 31 2024 | n/a | n/a | -US$364m |
| Dec 31 2023 | US$16m | US$273k | -US$339m |
Compensación vs. Mercado: La compensación total de Cameron($USD16.17M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.62M).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Cameron con los resultados de la empresa.
CEO
Cameron Turtle (34 yo)
less than a year
Permanencia
US$16,174,660
Compensación
Dr. Cameron Turtle, D.Phil. & Ph D., joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executiv...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | US$16.17m | 1.47% $ 19.8m | |
| Chief Financial Officer | less than a year | US$7.55m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | less than a year | US$6.93m | 0% $ 0 | |
| Senior Vice President of Operations | no data | sin datos | sin datos | |
| Chief Technical Officer | less than a year | sin datos | sin datos | |
| Vice President of Finance & Investor Relations | no data | sin datos | sin datos | |
| Vice President of Quality & Compliance | no data | sin datos | sin datos | |
| Senior Director of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Senior Vice President of Corporate Development | no data | sin datos | sin datos | |
| Senior Vice President of People | no data | sin datos | sin datos | |
| Consultant | 1.3yrs | US$865.79k | sin datos | |
| Senior Vice President of Clinical Development | less than a year | sin datos | sin datos |
0.9yrs
Permanencia media
44yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SYRE no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | less than a year | US$16.17m | 1.47% $ 19.8m | |
| Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Independent Chairman of the Board | less than a year | US$433.57k | 0.068% $ 913.0k | |
| Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Independent Director | 1.2yrs | US$658.43k | 0.80% $ 10.8m | |
| Independent Director | less than a year | sin datos | 0% $ 0 | |
| Independent Director | less than a year | US$434.38k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$660.78k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$661.28k | 0.80% $ 10.8m |
1.2yrs
Permanencia media
44yo
Promedio de edad
Junta con experiencia: La junta directiva de SYRE no se considera experimentada (1.2 años de permanencia promedio), lo que sugiere una nueva junta directiva.